Merkel cell polyomavirus-specific and CD39

CD8 T cells CyTOF MCPyV Merkel cell carcinoma Merkel cell polyomavirus TCR sequencing antigen-specific T cells checkpoint blockade high-dimensional analysis immunotherapy tumor-specific T cells

Journal

Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894

Informations de publication

Date de publication:
30 Jan 2024
Historique:
received: 03 07 2023
revised: 29 11 2023
accepted: 21 12 2023
medline: 11 2 2024
pubmed: 11 2 2024
entrez: 10 2 2024
Statut: aheadofprint

Résumé

Merkel cell carcinoma is a skin cancer often driven by Merkel cell polyomavirus (MCPyV) with high rates of response to anti-PD-1 therapy despite low mutational burden. MCPyV-specific CD8 T cells are implicated in anti-PD-1-associated immune responses and provide a means to directly study tumor-specific T cell responses to treatment. Using mass cytometry and combinatorial tetramer staining, we find that baseline frequencies of blood MCPyV-specific cells correlated with response and survival. Frequencies of these cells decrease markedly during response to therapy. Phenotypes of MCPyV-specific CD8 T cells have distinct expression patterns of CD39, cutaneous lymphocyte-associated antigen (CLA), and CD103. Correspondingly, overall bulk CD39

Identifiants

DOI: 10.1016/j.xcrm.2023.101390 PMID: 38340724
pubmed: 38340724
pii: S2666-3791(23)00619-5
doi: 10.1016/j.xcrm.2023.101390
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101390

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests E.W.N. is a co-founder, advisor, and shareholder for ImmunoScape Pte. Ltd., a scientific advisory board member and shareholder for Neogene Therapeutics, and a scientific advisory board member for Nanostring Biotechnologies and Trojan Biotechnologies. D.M.K. and P.N. are co-inventors on an institutionally owned patent concerning MCPyV-specific TCRs.

Auteurs

Heeju Ryu (H)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.

Timothy M Bi (TM)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.

Thomas H Pulliam (TH)

Department of Medicine, Division of Dermatology, University of Washington, Seattle, WA, USA.

Korok Sarkar (K)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.

Candice D Church (CD)

Department of Medicine, Division of Dermatology, University of Washington, Seattle, WA, USA.

Nandita Kumar (N)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Lab Medicine and Pathology, University of Washington, Seattle, WA, USA.

Koshlan Mayer-Blackwell (K)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.

Saumya Jani (S)

Department of Medicine, Division of Dermatology, University of Washington, Seattle, WA, USA; Department of Lab Medicine and Pathology, University of Washington, Seattle, WA, USA.

Nirasha Ramchurren (N)

Cancer Immunotherapy Trails Network, Fred Hutchinson Cancer Center, Seattle, WA, USA.

Ulla K Hansen (UK)

Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.

Sine R Hadrup (SR)

Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.

Steven P Fling (SP)

Cancer Immunotherapy Trails Network, Fred Hutchinson Cancer Center, Seattle, WA, USA.

David M Koelle (DM)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Lab Medicine and Pathology, University of Washington, Seattle, WA, USA; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA; Benaroya Research Institute, Seattle, WA, USA.

Paul Nghiem (P)

Department of Medicine, Division of Dermatology, University of Washington, Seattle, WA, USA.

Evan W Newell (EW)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Lab Medicine and Pathology, University of Washington, Seattle, WA, USA. Electronic address: enewell@fredhutch.org.

Classifications MeSH